BioMedNewsBreaks

FridayApr 16, 2021 1:48 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Offers Innovative Solution in Multibillion and Growing Market

Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a CAGR of 13.6%. These figures are according MarketsandMarkets, which cites several growth factors including technological advancements in fluid management systems (https://ibn.fm/rKWZC). As disposal of waste fluids presents a unique set of challenges for every health care facility, Skyline Medical offers a clear solution. Skyline’s patented and FDA-cleared STREAMWAY System is “the new standard in waste fluid management,” automating the collection, measurement and…

Continue Reading

FridayApr 16, 2021 1:24 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the…

Continue Reading

FridayApr 16, 2021 1:08 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Eyes Q2 Expansion of Growing Portfolio

Healthy Extracts (OTCQB: HYEX) recently released its full-year 2020 report. In addition to achieving a 71% jump in its revenue on the back of a plant-based industry boom, the company announced it was at an advanced stage of clinical testing that would culminate in the release of a new product in Q2 2021. The proprietary Fuel4Thought Brain Booster product will add to Health Extracts’ portfolio, which has increased thanks to acquisitions. An article on the developments reads, “Healthy Extracts acquired BergaMet NA in 2019, engaged in selling and distributing a full line of proprietary formulations derived from the rare Citrus…

Continue Reading

ThursdayApr 15, 2021 2:18 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. at Forefront to Speed Economic Recovery

United Medical Equipment (“UME,” “UMEBSNI”) is well-positioned to help speed up economic recovery with its FDA-approved COVID-19 rapid test kits. This comes as governments in different parts of the world have expressed interest in rapid testing, citing health and economic benefits. An article on the matter reads, “New York City is wasting no time to leverage the power of this low-cost, high impact option as the city has announced the launch of its Forward Rapid-Test Program. The program will make low-cost rapid testing available to the broader public to support economic recovery by enabling businesses to more safely re-open. The…

Continue Reading

ThursdayApr 15, 2021 12:09 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. The letter noted that AZRX is on track to launch its niclosamide programs in the clinic, noting that just this month the company announced the initiation of RESERVOIR, its Phase 2 clinical trial of niclosamide for the treatment of COVID-19-related gastrointestinal infections; the company also established an agreement with PPD Inc. (“PPD”), a leading clinical research organization, to manage the upcoming Phase 1b/2a ICI-AC trial, planned for Q2…

Continue Reading

ThursdayApr 15, 2021 11:39 am

BioMedNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ‘Covid-ID Lab’ Combines Speed of Rapid Screening with Accuracy of PCR Diagnostic

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus. XPhyto’s exclusive German diagnostics partner, 3a-diagnostics GmbH, developed Covid-ID Lab to provide rapid, accurate and portable testing capabilities, granting it marketability as a product with increased convenience and decreased operating costs.…

Continue Reading

ThursdayApr 15, 2021 11:22 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Delivering Readily-Available Solution Amid Growing Need

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, is fulfilling a growing need for improved neurological monitoring that is cost efficient, disposable and portable. When combating a highly contagious disease, disposable technology helps to ensure that the virus is not spread through equipment. Brain Scientific’s disposable EEG caps are designed for single use and also assist in shortening person-to-person contact due to ease of placement, decreasing transmission between staff and patient. “As health-care facilities and frontline workers move quickly to address COVID symptoms and provide effective treatment, disposable devices offer a solution to rapidly…

Continue Reading

ThursdayApr 15, 2021 11:11 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Targets $400M Slice of Massive Global Endoscopy Market

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has hailed its first product, the i/Blue(TM) Imaging System, as a breakthrough technology that will advance the accuracy and efficiency of bladder cancer detection and removal, thus helping it capture some market share. The global endoscopy market is valued at $46 billion, of which Imagin is positioned to target $400 million with its bladder cancer detection product. An article detailing this reads, “The company’s patented ultrasensitive imaging product based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.” According to…

Continue Reading

WednesdayApr 14, 2021 1:00 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was given for research conducted by and a paper written by Williams. The paper, which was published in “Proceedings of the National Academy of Science, USA,” was titled "Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.” The research identified the collagen VI…

Continue Reading

WednesdayApr 14, 2021 12:49 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Appoints Widely Acclaimed Leader as New Medical Director of Clinical Education

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. Guarneri is widely acclaimed as a leading Integrative cardiologist in America and is board-certified in cardiovascular disease, nuclear cardiology and internal and integrative holistic medicine. “We are very excited to welcome Dr. Guarneri to Vivos Therapeutics in this new capacity,” said Kirk Huntsman, Vivos’ chairman…

Continue Reading